Time course of clinical response to venlafaxine: Relevance of plasma level and chirality

European Journal of Clinical Pharmacology

Volumn 59, Issue 12, 2004, Pages 883-891

  Gex Fabry, Marianne ^a   Balant Gorgia, Androniki E ^a   Balant, Luc P ^a   Rudaz, Serge ^b   Veuthey, Jean Luc ^b   Bertschy, Gilles ^c  

^a Clinical Research Unit   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Concentration response relationship; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; CLORAZEPATE; DESVENLAFAXINE; DRUG METABOLITE; TRAZODONE; VENLAFAXINE; ZOPICLONE;

ADULT; ARTICLE; BLOOD SAMPLING; CHIRALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG RESPONSE; ENANTIOMER; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; RATING SCALE; REACTION TIME; STEADY STATE; STEREOCHEMISTRY; TIME; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STEREOISOMERISM;

EID: 1542511908     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0710-3     Document Type: Article

References (45)

1. Mendels J, Johnston R, Mattes J, Riesenberg R (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull 29:169-174
2. Kelsey JE (1996) Dose-response relationship with venlafaxine. J Clin Psychopharmacol 16:21S-26S
3. Rudolph RL, Fahre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT (1998) A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59:116-122
4. Preskorn SH (1994) Antidepressant drug selection: criteria and options. J Clin Psychiatry 55[Suppl A]:6-22
5. Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM (1998) The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol 18:19-25
6. Derivan A, Entsuah AR, Kikta D (1995) Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 31:439-447
7. Blier P, Bergeron R (1997) Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: are they related? Int Clin Psychopharmacol 12[Suppl3]:S21-S28
8. Nierenberg AA (2001) Do some antidepressants work faster than others? J Clin Psychiatry 62[Suppl15]:22-25
9. Roseboom PH, Kalin NH (2000) Neuropharmacology of venlafaxine. Depress Anxiety 12[Suppl1]:20-29
10. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G (1995) Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 56:450-457
11. Entsuah R, Derivan A, Kikta D (1998) Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther 20:517-526
12. Benkert O, Grunder G, Wetzel H, Hackett D (1996) A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 30:441-451
13. Entsuah AR, Huang H, Thase ME (2001) Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 62:869-877
14. Clerc GE, Ruimy P, Verdeau-Palles J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 9:139-143
15. Mehtonen OP, Sogaard J, Roponen P, Behnke K (2000) Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 61:95-100
16. Leon AC, Blier P, Culpepper L, Gorman JM, Hirschfeld RM, Nierenberg AA, Roose SP, Rosenbaum JF, Stahl SM, Trivedi MH (2001) An ideal trial to test differential onset of antidepressant effect. J Clin Psychiatry 62[Suppl4]:34-36
17. Katz MM, Halbreich UM, Bowden CL, Frazer A, Pinder RM, Rush AJ, Wheatley DP, Lebowitz BD (2002) Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. Neuropsychopharmacology 27:319-328
18. Blier P (2003) The pharmacology of putative early-onset anti-depressant strategies. Eur Neuropsychopharmacol 13:57-66
19. Tran PV, Bymaster FP, McNamara RK, Potter WZ (2003) Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 23:78-86
20. Harvey AT, Rudolph RL, Preskorn SH (2000) Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57:503-509
21. Muth EA, Haskins JT, Moyer JA, Husbands GE, Nielsen ST, Sigg EB (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493-4497
22. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, Turgeon J (2003) Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13:39-47
23. Gex-Fabry M, Rudaz S, Balant-Gorgia AE, Brachet A, Veuthey JL, Balant LP, Bertschy G (2002) Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. Eur J Clin Pharmacol 58:323-331
24. Charlier C, Pinto E, Ansseau M, Plomteux G (2002) Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. J Psychopharmacol 16:369-372
25. Veefkind AH, Haffmans PMJ, Hoencamp E (2000) Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 22:202-208
26. Hoencamp E, Haffmans J, Dijken WA, Huijbrechts IP (2000) Lithium augmentation of venlafaxine: an open-label trial. J Clin Psychopharmacol 20:538-543
27. Bertschy G, Ragama-Pardos E, Aït-Ameur A, Muscionico M, Favre S, Roth L (2003) Lithium augmentation in venlafaxine non-responders: an open study. Eur Psychiatry 18:314-317
28. Quitkin FM, Rabkin JG, Ross D, Stewart JW (1984) Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 41:782-786
29. Gibbons RD, Hedeker D, Waternaux C, Davis JM (1988) Random regression models: a comprehensive approach to the analysis of longitudinal psychiatric data. Psychopharmacol Bull 24:438-443
30. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. World Health Organization, Geneva
31. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389
32. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST (1996) Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 16:915-923
33. Rudaz S, Stella C, Balant-Gorgia AE, Fanali S, Veuthey JL (2000) Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in clinical samples by capillary electrophoresis using charged cyclodextrins. J Pharm Biomed Anal 23:107-115
34. Khan A, Khan SR, Shankles EB, Polissar NL (2002) Relative sensitivity of the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol 17:281-285
35. Hackett D (1998) Comparing onset of effect of antidepressants: pragmatic considerations on methods and end-points. Eur Psychiatry 13:117-123
36. Hedeker D, Gibbons RD (1996) MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors. Comput Methods Programs Biomed 49:229-252
37. Katz MM, Koslow SH, Frazer A (1996) Onset of antidepressant activity: reexamining the structure of depression and multiple actions of drugs. Depress Anxiety 4:257-267
38. Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Moller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 63:826-837
39. Schweitzer I, Burrows G, Tuckwell V, Polonowita A, Flynn P, George T, Theodoros M, Mitchell P (2001) Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol 21:185-189
40. Laska EM, Siegel C (1995) Characterizing onset in psychopharmacological clinical trials. Psychopharmacol Bull 31:29-35
41. Quitkin FM, Stewart JW, McGrath PJ, Nunes E, Ocepek-Welikson K, Tricamo E, Rabkin JG, Klein DF (1993) Further evidence that a placebo response to antidepressants can be identified. Am J Psychiatry 150:566-570
42. Lessard E, Yessine MA, Hamelin BA, O'Hara G, LeBlanc J, Turgeon J (1999) Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9:435-443
43. Thase ME (1999) Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 60[Suppl17]:28-31
44. Donovan SJ, Quitkin FM, Stewart JW, Ocepek-Welikson K, Harrison W, McGrath PJ, Nunes EV, Wager S, Tricamo E (1994) Duration of antidepressant trials: clinical and research implications. J Clin Psychopharmacol 14:64-66
45. Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Nelson J, Paykel E, Versiani M, Racagni G (2002) The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 12:461-475